Table 5.
Latanoprost concentration (μg/mL) | ||||
---|---|---|---|---|
|
50 |
75 |
100 |
125 |
N |
69 |
66 |
71 |
68 |
Worse eye | ||||
8 a.m. IOP | ||||
LS mean change (mmHg)* |
−37.6 |
−35.5 |
−37.3 |
−33.5 |
Difference in LS mean change ± SEM‡ |
|
2.2 ± 1.7 |
0.3 ± 1.7 |
4.1 ± 1.7 |
(90% CI) |
|
(−0.06, 5.0) |
(−2.4, 3.1) |
(1.3, 6.8) |
p-value‡ |
|
0.899 |
0.581 |
0.992 |
Study eye | ||||
8 a.m. IOP | ||||
LS mean change (mmHg)* |
−37.2 |
−35.0 |
−36.4 |
−33.3 |
Difference in LS mean change ± SEM‡ |
|
2.2 ± 1.7 |
0.8 ± 1.6 |
3.8 ± 1.6 |
(90% CI) |
|
(−0.6, 4.9) |
(−1.9, 3.4) |
(1.1, 6.5) |
p-value‡ | 0.906 | 0.682 | 0.990 |
ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
*Adjusting for baseline IOP (covariate) with dose group and center as factors.
‡Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
‡One-sided p-value.